IFNγ restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-κB, BCL2 family members, and signaling to caspase-dependent apoptosis

Molecular Cancer Therapeutics

Volumn 9, Issue 5, 2010, Pages 1274-1285

  Ning, Yanxia ^a,b   Riggins, Rebecca B ^a   Mulla, Jennifer E ^a   Chung, Haniee ^a   Zwart, Alan ^a   Clarke, Robert ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CASPASE; CASPASE 7; CASPASE 8; CASPASE 9; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 27; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; SMALL INTERFERING RNA; STAT1 PROTEIN; TRANSCRIPTION FACTOR RELA; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ESTRADIOL; IRF1 PROTEIN, HUMAN; STAT1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN FAMILY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CARCINOMA; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA; CASPASES; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON-GAMMA; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 77952162111     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1169     Document Type: Article

References (55)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Clarke R, Liu MC, Bouker KB, et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003; 22:7316-7339
3. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001;53:25-71. (Pubitemid 32173107)
4. Riggins R, Bouton AH, Liu MC, Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm 2005;71: 201-237
5. Howell A, DeFriend D, Robertson JFR, Blamey RW, Walton P. Response to a specific antioestrogen (ICI 182,780) in tamoxifenresistant breast cancer. Lancet 1995;345:29-30.
6. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-238
7. Vergote I, Robertson JF. Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials. Br J Cancer 2004;90 Suppl 1: S11-4.
8. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci U S A 1990;87:6883-6887
9. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci U S A 1992;89:4037-4041
10. Wakeling AE, Bowler J. Novel antioestrogens without partial agonist activity. J Steroid Biochem 1988;31:645-653
11. Brunner N, Boulay V, Fojo A, Freter CE, Lippman ME, Clarke R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 1993;53:283-290
12. Brünner N, Boysen B, Jirus S, et al. MCF7/LCC9: an antiestrogen resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early crossresistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 1997;57:3486-3493
13. Bronzert DA, Greene GL, Lippman ME. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 1985;117:1409-1417
14. Clarke R, Brünner N, Thompson EW, et al. The inter-relationships between ovarian-independent growth, antiestrogen resistance and invasiveness in the malignant progression of human breast cancer. J Endocrinol 1989;122:331-340
15. Gu Z, Lee RY, Skaar TC, et al. Association of interferon regulatory factor-1, nucleophosmin, NF-κB, and cyclic AMP response element binding with acquired resistance to faslodex (ICI 182,780). Cancer Res 2002;62:3428-3437
16. Tamura T, Ishihara M, Lamphier MS, et al. An IRF1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995;376:596-599
17. Tanaka N, Ishihara M, Kitagawa M, et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF1. Cell 1994;77:829-839
18. Tanaka N, Ishihara M, Lamphier MS, et al. Cooperation of the tumour suppressors IRF1 and p53 in response to DNA damage. Nature 1996;382:816-818
19. Moro A, Santos A, Arana MJ, Perea SE. Activation of the human p27 (Kip1) promoter by IFNα 2b. Biochem Biophys Res Commun 2000; 269:31-34
20. Bouker KB, Skaar TC, Riggins R, et al. Interferon regulatory factor-1 (IRF1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 2005;26:1527-1535
21. Sanceau J, Hiscott J, Delattre O, Wietzerbin J. IFN-β induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF1 and activation of caspase-7. Oncogene 2000;19:3372-3383
22. Chow WA, Fang JJ, Yee JK. The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. J Immunol 2000;164:3512-3518
23. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994;32:39-47.
24. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;399:1-15.
25. Bouker KB, Skaar TC, Fernandez DR, O'Brien KA, Clarke R. Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (Faslodex, Fulvestrant). Cancer Res 2004;64:4030-4039
26. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987;56:727-777
27. Darnell JE, Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-1421
28. Li X, Leung S, Qureshi S, Darnell JE, Jr., Stark GR. Formation of STAT1-2 heterodimers and their role in the activation of IRF1 gene transcription by interferon-α. J Biol Chem 1996;271:5790-5794
29. van den Berg HW, Leahey WJ, Lynch M, Clarke R, Nelson J. Recombinant human interferon α increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitises them to the anti-proliferative effects of tamoxifen. Br J Cancer 1987;55:255-257
30. Sica G, Natoli V, Stella C, Del Bianco S. Effect of natural β-interferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer 1987;60:2419-2423
31. Goldstein D, Bushmeyer SM, Witt PL, Jordan VC, Borden EC. Effects of type I and II interferons on cultured human breast cells: interactions with estrogen receptors and with tamoxifen. Cancer Res 1989;49:2698-2702
32. Wilson BE, Mochon E, Boxer LM. Induction of BCL2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 1996;16:5546-5556
33. Heckman CA, Mehew JW, Ying GG, Introna M, Golay J, Boxer LM. A-Myb up-regulates BCL2 through a Cdx binding site in t(14;18) lymphoma cells. J Biol Chem 2000;275:6499-6508 (Pubitemid 30129948)
34. Ning Y, Chen S, Li X, Ma Y, Zhao F, Yin L. Cholesterol, LDL, and 25-hydroxycholesterol regulate expression of the steroidogenic acute regulatory protein in microvascular endothelial cell line (bEnd.3). Biochem Biophys Res Commun 2006;342:1249-1256
35. Riggins R, Zwart A, Nehra R, Agarwal P, Clarke R. The NFkB inhibitor parthenolide restores ICI 182,780 (Faslodex;Fulvestrant)-induced apoptosis in antiestrogen resistant breast cancer cells. Mol Cancer Ther 2005;4:33-41.
36. NIH ImageJ. Available from: http://rsb.info.nih.gov/ij.
37. Nehra R, RIggins RB, Shajahan AN, Zwart A, Crawford AC, Clarke R. BCL2 and CASP8 regulation by NFkB differentially affect mitochondrial function and cell fate in antiestrogen senstiive and resistant breast cancer cells. FASEB J 2010, [epub before print; PMID 20154269].
38. Kovarik P, Stoiber D, Novy M, Decker T. Stat1 combines signals derived from IFN-γ and LPS receptors during macrophage activation. EMBO J 1998;17:3660-3668 (Pubitemid 28327384)
39. Lim KB, Ng CY, Ong CK, et al. Induction of apoptosis in mammary gland by a pure anti-estrogen ICI 182780. Breast Cancer Res Treat 2001;68:127-138
40. Somai S, Chaouat M, Jacob D, et al. Antiestrogens are pro-apoptotic in normal human breast epithelial cells. Int J Cancer 2003;105:607-612 (Pubitemid 36687727)
41. Cartharius K, Frech K, Grote K, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21:2933-2942 (Pubitemid 40916416)
42. Pizzoferrato E, Liu Y, Gambotto A, et al. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res 2004;64: 8381-8388
43. Stang MT, Armstrong MJ, Watson GA, et al. Interferon regulatory factor-1-induced apoptosis mediated by a ligand-independent fasassociated death domain pathway in breast cancer cells. Oncogene 2007;26:6420-6430
44. Bowie ML, Dietze EC, Delrow J, et al. Interferon-regulatory factor-1 is critical for tamoxifen-mediated apoptosis in human mammary epithelial cells. Oncogene 2004;23:8743-8755 (Pubitemid 39593289)
45. Kim PKM, Armstrong M, Liu Y, et al. IRF1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo. Oncogene 2004;23:1125-1135 (Pubitemid 38269966)
46. Connett JM, Badri L, Giordano TJ, Connett WC, Doherty GM. Interferon regulatory factor 1 (IRF1) and IRF-2 expression in breast cancer tissue microarrays. J Interferon Cytokine Res 2005;25:587-594 (Pubitemid 41507814)
47. Zhu Y, Singh B, Hewitt S, et al. Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor κ B, nucleophosmin, estrogen receptor α and progesterone receptor proteins in breast cancer tissue microarrays. Int J Oncol 2006;28:67-76.
48. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
49. Pine R. Convergence of TNFγ and IFNγ signalling pathways through synergistic induction of IRF1/ISGF-2 is mediated by a composite GAS/κB promoter element. Nucleic Acids Res 1997;25:4346-4354
50. Kumar A, Yang Y-L, Flati V, et al. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion of the PKR gene: role of IRF1 and NFkB. EMBO J 1997;16:406-416
51. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Sledge GW. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-3639
52. Pratt MAC, Bishop TE, White D, et al. Estrogen withdrawal-induced NF-κB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol 2003;23: 6887-6900 (Pubitemid 37220039)
53. Youle RJ, Strasser A. The BCL2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
54. Mirjolet JF, Barberi-Heyob M, Didelot C, et al. BCL2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. Br J Cancer 2000;83:1380-1386
55. Crawford AC, Riggins RB, Shajahan AN, Zwart A, Clarke R. Coinhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. PLoS ONE 2010;5:e8604.